AccessClosure Launches Mynx M5 Vascular Closure Device


June 22, 2009—AccessClosure, Inc. (Mountain View, CA) announced the launch of the Mynx M5 vascular closure device, which can be delivered directly through a 5-F cardiovascular sheath without enlarging the arterial hole or traumatizing the surrounding tissue in the process. This approach also eliminates the need for a sheath exchange, saving procedure time and expense. AccessClosure noted that the Mynx vascular closure product line was first approved by the US Food and Drug Administration for 6- and 7-F cardiovascular procedures in May 2007.

According to the company, the Mynx design minimizes the discomfort commonly associated with vascular closure due to its deployment method and sealant material. The Mynx uses a soft, bioabsorbable polymer sealant material, polyethylene glycol, which has been used safely in a wide range of medical products such as gel caps and eye drops. During the closure procedure, the sealant is placed over the arterial puncture area. The sponge-like sealant expands three to four times its original size by rapidly absorbing blood around the puncture site and then stops the bleeding and seals the artery. The sealant then dissolves naturally within 30 days, the company stated.

"Before the Mynx M5, existing closure devices required the physician to create a larger hole in the artery just to seal it in diagnostic cases," commented Dharmesh Patel, MD. "The M5 specifically addresses the primary clinical need for the 5-F market, which is to reliably close the puncture site without enlarging it first. This is particularly useful in my practice, allowing patients to ambulate quicker with greater safety and tolerability."

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.